https://www.selleckchem.com/products/cq211.html
Primary pharmacokinetic results from part1 supported modification of the part2 study design. Results from part2 demonstrated that etrolizumab exposure was equivalent between devices, with geometric mean ratios (GMRs) between AI and PFS-NSD of 102% (90% confidence interval [CI] 94.2-111) for C , 98.0% (90% CI 89.3-107) for AUC , and 97.6% (90% CI 88.6-107) for AUC . Median t and mean terminal t were also similar between devices. GMRs and 90% CIs of all primary pharmacokinetic parameters were fully contained within the predefined equivalenc